Shin Nippon Biomedical Laboratories, Ltd.'s Form 4 filing
Satsuma Pharmaceuticals, Inc.STSA · filed Jun 8, 2023
- Accession no.
- 0000899243-23-014866
- Filed
- Jun 8, 2023
- Trade date
- Jun 6-8, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $27.7M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shin Nippon Biomedical Laboratories, Ltd.CIK 0001657770 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 6, 2023 | Common Stock | PPurchaseAcquired | +22,053,581 | $0.91 | +$20,068,758.71 | 22,053,581 | Indirect | |
| Jun 8, 2023 | Common Stock | PPurchaseAcquired | +8,423,732 | $0.91 | +$7,665,596.12 | 8,423,732 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.